Protocol Ledger

NCT05718323 · Phase II · RECRUITING

Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

Interventional Phase II clinical trial protocol NCT05718323 sponsored by ETOP IBCSG Partners Foundation in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-20 Enrollment: 44 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05718323
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)44 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05718323
Protocol FieldVerified Registry Value
NCT IdentifierNCT05718323
Consolidated Lead SponsorETOP IBCSG Partners Foundation
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment44 participants (ESTIMATED)
Registered Start Date2023-12-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05718323
Hospital Research SiteLocationSite Profile
CHU AngersAngers, FranceOpen Hospital Dossier ->
Complejo Hospitalario Universitario A CoruñaA Coruña, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI